Key Words: antidepressive agents, anti-anxiety agents, depression, family practice, multilevel model, practice guidelines E pidemiologic studies show that GPs are likely to prescribe benzodiazepines (anxiolytics or hypnotics) to patients with major depression. [1] [2] [3] Depressed patients in mental health settings commonly receive benzodiazepines in combination with ADs. 4 To our knowledge, however, no studies have documented the extent to which GPs in office-based practice prescribe benzodiazepines together with ADs. 5 Some official references, for example, the Physicians' Desk Reference, 6 state that anxiety associated with depression is responsive to some benzodiazepines (entry for alprazolam), while others do not recognize this indication (Dictionnaire Vidal, same entry). 7 The American Psychiatric Association's practice guideline for the treatment of MDD suggests using benzodiazepines with caution in the treatment of MDD and recommends that, in general, benzodiazepines should not be used as the primary pharmacologic agent for MDD and anxiety symptoms, especially in patients with more severe forms of MDD. 8 The Canadian Psychiatric Association and Canadian Network for Mood and Anxiety Treatments recommend specific SSRIs or novel agents such as venlafaxine as first-line treatment for depression with serious anxiety symptoms. 9 Most randomized clinical trials examining benzodiazepines as the primary pharmacologic treatment for MDD have concluded that benzodiazepines alone are less effective than ADs, as they address sleeplessness and restlessness but not the core symptoms of MDD. 10 They might also have such side effects as dependence, including withdrawal symptoms if discontinued rapidly in long-term users, cognitive impairments in acute and perhaps in chronic use, increased risks of motor vehicle crashes, and falls and hip fractures, especially in the elderly. 4, 11 In combined treatment, however, benzodiazepines might contribute to AD response in the first weeks because they produce a faster onset of effect on anxiety symptoms than ADs alone, or because they affect different symptoms. 10 Moreover, a metaanalysis of the available randomized controlled trials showed that, compared with ADs alone, coprescription of benzodiazepines with ADs increases patient adherence to treatment and significantly reduces premature drop-out rates, 12 an important result given that 30% to 70% of depressed patients end their AD treatment early. 13, 14 We conducted a study among GPs in southeastern France with the following 2 aims. First, to evaluate GPs' actual anxiolytic coprescription practices when starting patients on AD treatment, we focused on anxiolytics because they are the most frequently used psychotropic drug in France, 15, 16 and we sought to understand GPs' intentions and reasons for coprescribing these drugs with an AD. Second, we wanted to identify factors associated with GPs' anxiolytic coprescription. In particular, we intended to answer the following questions. Do GPs coprescribe anxiolytics more frequently in patients with specific clinical characteristics, such as high anxiety levels, suicidality, or psychiatric comorbidity? Are they influenced by patients' demographic and social characteristics? 17 Do their practices vary according to their own characteristics, such as training, perceived comfort in treating MDD, 18 MDD, anxiety disorders, and attempted suicide, or for whom they had prescribed ADs. GPs were asked to complete a consultation-questionnaire for each patient who met the inclusion criteria. It sought the patient's expressed reason(s) for consultation; GP's diagnosis of MDD, anxiety disorder, chronic pain, comorbid physical conditions, alcoholism, or substance abuse; AD prescribed and instructions given for its usage; and any anxiolytics that may have been coprescribed with it. The consultation-questionnaire also included an item about the patient's history of suicide attempts (yes or no), suicidal plans or ideation (yes or no), DSM-IV criteria for current MDD and anxiety disorders, and a GAF scale to rate the patient's functioning (from 0 for very poor, to 10 for very good). 22 We also asked GPs to select a reason for coprescribing anxiolytics with antidepressants (high level of anxiety, insomnia, agitation, patient already receiving anxiolytics, risk of suicide, or "because this is part of depression treatment"), and to report the length of the consultation. Finally, we asked them to give each patient included a questionnaire to be completed at home and sent back to our team by prepaid return mail. This questionnaire included the HAD, 23 the MDD module of the self-administered Composite International Diagnostic Interview, 24 2 modules of the SF36 life quality questionnaire (Social Functioning and Emotional Role), 25 the DETA (an acronym from diminuer, entourage, trop, alcohol), the validated French version of the CAGE (an acronym from cut, annoyed, guilty, and eye-opener) screening questionnaire for alcohol dependency, 26 and social and demographic characteristics. We also assessed suicidal ideation, defined as a positive answer to either of the following items from the Beck Depression Inventory 27 : "I think that death would free me," or "I have specific plans to commit suicide."
We mailed questionnaires and written instructions explaining the protocol to the GPs who agreed to participate. Professional interviewers then called them to verify they had received the material and to explain the procedure, and thereafter telephoned weekly to check inclusions. At the end of the survey, GPs returned their consultation-questionnaires by prepaid return mail. Physicians received an indemnification for the time spent completing questionnaires. Patients did not receive incentives. In compliance with French law, details about the data collection protocol and procedures guaranteeing anonymity were reported to and approved by the national Commission for Computer Privacy.
Statistical Analysis
We used the chi-square test and Student t test statistics for univariate comparisons of qualitative and quantitative variables, respectively. We studied potential associations between sex, of patients and GPs, and prevalence of anxiolytic coprescription and its reasons. We constructed a multilevel model of the factors associated with GPs' coprescription of anxiolytics with ADs (the dependent variable) to take into account the 2-level data structure (patient-consultation and GPs' characteristics). 28 We first used simple logistic regressions to test self-reported patient variables (social and demographic characteristics, HAD depression and anxiety scores, suicidal ideation, social functioning and role emotional, and psychiatric comorbidity) and patient characteristics, as well as symptoms and morbidity, as assessed by GPs during the consultation. We then entered the variables significant at P £ 0.15 at the previous step in backward multiple logistic regressions (exit threshold: P > 0.05). Forward multiple logistic regressions produced the same results. We finally used a 2-level logistic model of the variables significant at the previous step and GPs' characteristics. The latter were introduced as predictors of the intercept parameter, to test a fixed effect for all patients. We used SAS v9.1 and STATA v9 software for descriptive statistics and logistic regressions, and HLM-v6 software for the multilevel regressions.
Results
In all, 131/542 GPs (24.2%) sent back 438 consultationquestionnaires for patients whom they had started on an AD; 258 patients (58.9%) returned their self-report questionnaires. The proportion of women was higher among the participating GPs than among nonparticipants (see Table 1 ). Participants and nonparticipants did not significantly differ for age or for place of practice (rural, compared with other areas). Patients who returned their self-questionnaire did not differ for sex, age, GAF score, or anxiety disorders (diagnosed by the GPs) from patients who did not; they tended to be more frequently diagnosed with MDD by GPs, although this difference was not significant (see Table 1 ).
Overall, GPs diagnosed MDD in 77.9% of patients, anxiety disorders in 29.3%, chronic pain in 4.7%, and comorbid MDD with an anxiety disorder in 34.4%. Sixty percent of patients (95%CI, 54% to 66%) received an anxiolytic with the AD. This percentage did not differ significantly according to patient sex, even when we separately considered patients of male and female GPs (see Table 2 ). The most frequent reasons given by GPs for the combination were that the patient was anxious or had insomnia; the distribution of their answers varied significantly with patients' sex (for agitation and insomnia) but not with GPs' sex (see Table 3 ). The mean consultation length was higher for female GPs than for male First-level simple logistic regressions showed that anxiolytic coprescriptions were significantly less frequent for patients who were older, or whose reasons for consulting were physical symptoms (as opposed to psychological symptoms) or for those with unstable jobs, or who were unemployed or retired, compared with those with stable jobs (see Table 4 ).
Coprescription was significantly more frequent when GPs detected symptoms of anxiety or, at the limit of significance, sleep disorders or suicidal ideation in their patients. In the first-level multiple logistic model, only patient work status, GP-detected suicidal ideation, and GP-detected anxiety remained associated with anxiolytic coprescription.
In the final 2-level model (see Table 5 ), coprescription of anxiolytics was more frequent when GPs were men, or when GPs reported uneasiness in treating MDD, or detected suicidal ideation or anxiety in their patients. Finally, we observed the same association with work status as we did in the first-level logistic regression. We found no relation with other GP-related variables, in particular, with continuing medical education training.
Discussion
Our data show that 60% of the patients starting AD treatment receive anxiolytic coprescriptions. This far exceeds the prevalence of benzodiazepine use (36%) observed in a study of American veterans (mostly men) treated in mental health settings for depressive disorders. 4 This high coprescription rate is worrisome, because a significant portion of the patients might continue the treatment for a period longer than several weeks and might thus increase the risk of side effects. After anxiety, insomnia was unexpectedly the second most frequent motive reported by GPs for justifying this coprescription. Although anxiolytics and hypnotics have specific authorized indications, our result suggests that GPs might not distinguish strictly between them; this might be due in part to the overlap between their pharmacologic effects (more or less pronounced sedative effect of anxiolytics).
Male GPs prescribed anxiolytics when starting ADs more frequently than female GPs. This association was not due to prescription differences according to patient sex (see Table 2 ). It might be due to a lower prescription rate by female GPs in general, compared with male GPs, 29 and to differences between them in attitudes and therapeutic approaches, as already seen in the mental health field. 19 Although we observed a higher mean consultation length for female GPs, consistent with previous research, 30 this variable was not associated with anxiolytic coprescription in the final model.
Independent of sex, GPs who reported discomfort with treating MDD coprescribed anxiolytics with ADs significantly more frequently than GPs who did not report such feelings. This result did not depend on GPs' age. This uneasiness might reflect a lack of training, as shown in another field of medical practice. 31 GPs who feel uneasy might be prescribing anxiolytics because they are less prepared or less likely to consult a specialist or explain side effects of anxiolytics to the patient.
It is not clear why GPs coprescribed anxiolytics more often for patients with stable jobs than for those with unstable or no jobs or retired. We hypothesize that patients with regular jobs might demand more symptomatic relief than patients in other situations and GPs might consider anxiety and sleep problems (especially in men, Table 3 ) as target symptoms in these patients, compared with unemployed patients. The potential for abuse might be another reason GPs were less likely to prescribe anxiolytics to unemployed patients. This finding suggests the possibility of a stereotype or stigma of unemployment.
The multilevel analysis showed that GPs coprescribed anxiolytics more frequently when they detected DSM-IV criteria for anxiety disorders than when they did not (see Table 5 ). A high level of anxiety was also their leading reason for coprescribing an anxiolytic (see Table 3 ). This is in line with the French practice guidelines for the treatment of MDD, which permit prescription of anxiolytics when initiating AD treatment in such situations. 32, 33 However, some authors and other practice guidelines recommend SSRIs alone as first-line treatment. 8, 9, 34, 35 We did not find any significant association between anxiolytic coprescriptions and anxiety assessed according to the anxiety score of the self-administered HAD scale. Anxiety drugs, however, take effect rapidly, so that anxiety levels might be higher during the consultation than afterwards, when patients have taken their anxiety medication.
The multilevel analysis showed that GPs coprescribed anxiolytics when they identified suicidal ideation in their patients. GPs might fear that prescribing an AD might give some patients the motivation and energy to act on impulses or desires that their depression had previously kept them from acting on. This was taught in medical schools decades ago 8, 36 and was raised again more recently by the debate about the possible increase in suicidality induced by SSRIs. Recent data on adolescents and metaanalyses of results from adults have reopened this debate and moved it to the health policy arena and popular media. 5, 37, 38 A Canadian Psychiatric Association position statement considers, as do some regulatory agencies, 33 that there is little peer-reviewed evidence that SSRIs induces an increase in suicidality in adults. 39 The coprescription of anxiolytics in such situations appears consistent with the French practice guideline for the treatment of MDD 32 and with Rihmer and Akiskal's recommendation that ADs not be prescribed alone in such situations. They recommend adding mood stabilizers or even benzodiazepines 5 because increased suicidality might be related to an activation syndrome (increasing activity before improvement of mood). However, we did not find any association between anxiolytic coprescription and suicidality for patients reporting suicidal ideas in the self-report questionnaire. Substantial underdetection of suicidal ideas in general practice 21 might explain this discrepancy. GPs' reasons for coprescribing anxiolytics (see Table 3 ) might thus be provided as justifications and not accurately reflect the patients' mental state.
The participation rate of GPs in this study was low (24%), as expected, given the frequently low response rates in postal surveys in primary practice, especially in France. 40 A selection bias in our sample is thus possible. The proportion of women was significantly higher among participating GPs than in the initial panel. Moreover, GPs who participated in this study might be more concerned about mental health problems than those who did not participate and their practices might thus differ. The mean rate of new AD prescriptions was 1.6 per month per GP in our study, but we note that all GPs did not participate for the same duration during the study period; some took summer holidays and continued others withdrew from the study after the summer. Regional health insurance fund reimbursement data for a similar period in 2005 showed a slightly higher rate (2.0 new AD prescriptions per month per GP). These rates are nonetheless close. These data also show that the distribution of the rate of new AD prescriptions per GP was very similar to that of our study during a similar period. Finally, the data show that one-half of all patients receiving a new AD prescription also received an anxiolytic prescription. The percentage (60%) is higher in our study; however, the order of magnitude is the same. These results indicate that a fairly representative sample of physicians completed the consultation-questionnaires. The patient participation rate was acceptable (59%), and participants and nonparticipants did not differ significantly in their demographic characteristics, GAF scale score, or percentage of anxiety disorders (as evaluated by the GPs). Finally, a cross-sectional study such as this one cannot show what happens after AD treatment starts or how long anxiolytic treatment lasts. The study design did, however, allow us to study GPs' actual prescription practices for patients under their usual consultation conditions. It also allowed us to examine a large number of AD prescriptions together with rich data on GPs and patients.
Conclusion
The reasons GPs choose to coprescribe anxiolytics with ADs at treatment initiation for MDD are complex. They are linked not only to patients' specific clinical features but also to their socioeconomic characteristics (work status) and to GPs'
Original Research characteristics and attitudes (sex and uneasiness in treating MDD).
Some practice guidelines and authors acknowledge that there might be some justification for coprescribing anxiolytics with ADs at the beginning of MDD treatment in specific situations. However, discrepancies appear to exist between authorized indications, practice guidelines, and physician practices regarding this question. The high percentage of coprescriptions for anxiolytics observed in our study suggests, however, that French GPs have less than optimal training and knowledge about MDD treatment, especially regarding treatment strategies for complex situations such as depression with high anxiety levels and suicidal ideation. In these situations, seeking advice from psychiatrists or developing shared-care practices with them might also improve patient care and should be encouraged.
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Résumé : Les déterminants de la co-prescription d'anxiolytiques et d'antidépresseurs dans la pratique générale
Objectifs : Les anxiolytiques sont les médicaments psychotropes les plus souvent prescrits en France. Les omnipraticiens (OP) tendent à prescrire des anxiolytiques et autres benzodiazépines aux patients souffrant de troubles dépressifs majeurs (TDM). Cependant, la mesure dans laquelle ils prescrivent ces médicaments ensemble, et les raisons qui les motivent ne sont pas bien documentées. Cet article évalue à quelle fréquence et pourquoi les OP co-prescrivent un anxiolytique quand ils commencent un traitement d'antidépresseur pour un patient, et quels facteurs liés au patient et à l'OP sont associés à cette co-prescription.
Méthodes : Nous avons utilisé un sondage mené auprès de 131 OP exerçant dans le Sud-Est de la France, et de patients vus consécutivement de juin à octobre 2004 à qui ils avaient prescrit un antidépresseur. Les données ont été recueillies auprès des OP (questionnaires de consultation axés sur leur prescription, diagnostic, et détection de symptômes) et des patients (questionnaires auto-administrés, comprenant l'échelle de mesure des troubles anxieux et dépressifs lors de l'hospitalisation [échelle HAD] et les caractéristiques sociodémographiques). Les facteurs associés à la co-prescription d'un anxiolytique ont été analysés à l'aide d'une régression logistique multiniveau.
Résultats : Les OP ont rempli 438 questionnaires de consultation pour les patients; 258 patients (58,9 %) ont retourné leurs questionnaires. Soixante pour cent des patients recevaient des anxiolytiques avec des antidépresseurs. Les anxiolytiques étaient plus souvent prescrits par les OP masculins qui déclaraient être mal à l'aise de traiter le TDM, ou qui détectaient une idéation suicidaire ou de l'anxiété chez leurs patients et finalement, aux patients ayant des emplois stables.
Conclusions :
Bien que certains guides de la pratique et des auteurs reconnaissent qu'il puisse être justifié de co-prescrire anxiolytiques et antidépresseurs au début d'un traitement de TDM dans des situations spécifiques, le pourcentage élevé de co-prescriptions d'anxiolytiques observé dans notre étude suggère que la formation et les connaissances des OP au sujet du traitement du TDM ne sont pas optimales.
